Unicycive Therapeutics In...

0.61
0.01 (1.62%)
At close: Apr 21, 2025, 3:59 PM
0.62
1.33%
After-hours: Apr 21, 2025, 06:02 PM EDT
1.62%
Bid 0.6
Market Cap 73.18M
Revenue (ttm) n/a
Net Income (ttm) -42.65M
EPS (ttm) -0.56
PE Ratio (ttm) -1.09
Forward PE 0.6
Analyst Buy
Ask 0.65
Volume 729,853
Avg. Volume (20D) 984,965
Open 0.60
Previous Close 0.60
Day's Range 0.60 - 0.63
52-Week Range 0.20 - 1.29
Beta 2.15

About UNCY

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California....

Industry Biotechnology
Sector Healthcare
IPO Date Jul 12, 2021
Employees 22
Stock Exchange NASDAQ
Ticker Symbol UNCY
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for UNCY stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 881.51% from the latest price.

Stock Forecasts
5 months ago
+20.24%
Unicycive Therapeutics shares are trading higher a... Unlock content with Pro Subscription
10 months ago
-26.76%
Unicycive Therapeutics shares are trading lower. The company announced results from the Oxylanthanum Carbonate UNI-OLC-201 pivotal clinical trial.